For acute lymphoblastic leukemia (ALL), therapy with a tyrosine kinase inhibitor, such as Imatinib, is assumed to be highly beneficial in the presence of an BCR:ABL translocation [9]. Here, BCR is linked to acute lymphoblastic leukemia.